MTD211

MTD211 is an investigational **long-acting injectable formulation of brexpiprazole** being developed by Biodexa using its Q-Sphera drug-delivery technology. Brexpiprazole is an atypical antipsychotic small molecule whose pharmacology is characterized primarily by **partial agonism at serotonin 5-HT1A and dopamine D2 receptors** and **antagonism at serotonin 5-HT2A and adrenergic alpha-1B and alpha-2C receptors**. MTD211 is intended to sustain therapeutic brexpiprazole exposure for about three months after a single injection, with development aimed at psychiatric indications including **schizophrenia** and **major depressive disorder** as an adjunctive treatment setting. Publicly available pipeline summaries describe the asset as an early clinical or pre-Phase 1 program rather than an approved product.

Other names

long-acting brexpiprazole